Strategic Partnership TherapeuticsMD recently entered an exclusive US license agreement with Mayne Pharma for its women's health portfolio, presenting an opportunity for collaborative sales strategies and leveraging each other's expertise in the pharmaceutical industry.

Investment Boost Rubric Capital Management has shown confidence in TherapeuticsMD by providing significant investments, such as a $7 million equity investment and additional financing, indicating interest in the company's growth potential and product offerings.

High-Profile Hiring With the appointment of Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers, TherapeuticsMD is poised for strategic leadership, potentially opening doors for partnerships, collaborations, and new sales opportunities.

Asset Sale The recent sale of assets to Mayne Pharma for estrogen replacement medication, menopause medication, and prenatal vitamin products indicates a shift in focus for TherapeuticsMD, paving the way for new product development and potential sales avenues in other therapeutic areas.

Financial Stability Despite a decrease in headcount, TherapeuticsMD's ability to secure funding and maintain a revenue range of $50-100 million showcases financial stability, which can serve as a strong selling point and instill confidence in potential partners or investors.